HER2
2000; Elsevier BV; Volume: 36; Issue: 14 Linguagem: Inglês
10.1016/s0959-8049(00)00162-3
ISSN1879-0852
AutoresMartine Piccart, Angelo Di Leo, A. Hamilton,
Tópico(s)Breast Cancer Treatment Studies
ResumoThe past few years have witnessed an exponential increase in studies trying to identify molecular markers in patients with breast tumours that might predict for the success or failure of hormonal therapy or chemotherapy. HER2, a tyrosine kinase membrane receptor of the epidermal growth factor receptor family, has been the most widely studied marker in this respect. This paper attempts to critically review to what extent HER2 may improve 'treatment individualisation' for the breast cancer patient.
Referência(s)